Technical Standards for Breast Cancer Surgery: Utilizing Operative Standards in a Changing Clinical Landscape
September 12, 2023
The CSSP will host an educational webinar for surgeons on the technical standards for breast cancer surgery. This webinar will discuss evidence-based operative standards for the performance of breast cancer surgery as outlined in the Operative Standards for Cancer Surgery, Volume 1. This will include review of technical standards and the rationale supporting these recommendations. The discussion will include insights into clinical management of breast cancer and applicable controversies.
All surgeons who view the webinar via the ACS Learning Management System are eligible to receive 1.0 Continuing Medical Education (CME) credits. We encourage staff at CoC-accredited cancer programs to share this information with surgeons, trainees, and fellows with an interest in breast cancer surgery.
The American College of Surgeons is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The American College of Surgeons designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This forum will discuss evidence-based operative standards for the performance of breast cancer surgery as outlined in the Operative Standards for Cancer Surgery, Volume 1. This will include review of technical standards and the rationale supporting these recommendations. The discussion will include insights into clinical management of breast cancer and applicable controversies.
At the completion of the activity, participants should be able to:
In accordance with the ACCME Accreditation Criteria, the American College of Surgeons must ensure that anyone in a position to control the content of the educational activity (planners and speakers/authors/discussants/moderators) has disclosed all financial relationships with any commercial interest (termed by the ACCME as “ineligible companies”, defined below) held in the last 24 months (see below for definitions). Please note that first authors were required to collect and submit disclosure information on behalf all other authors/contributors, if applicable.
The ACCME also requires that ACS manage any reported conflict and eliminate the potential for bias during the educational activity. Any conflicts noted below have been managed to our satisfaction. The disclosure information is intended to identify any commercial relationships and allow learners to form their own judgments. However, if you perceive a bias during the educational activity, please report it on the evaluation.
Kelly Hunt, MD – Research support from Cairn Surgical, Eli Lilly & Co., and Lumicell. Medical Advisory Board member AmadaHealth, AstraZenica, Merck & Co.
Katharine Yao, MD - (Nothing to disclose)
Puneet Singh, MD - (Nothing to disclose)
Lyndsey Kilgore, MD - (Nothing to disclose)
Makesha Miggins, MD - (Nothing to disclose)
Mediget Teshome, MD - Conference attendance at the transatlantic breast cancer conference.
Puneet Singh, MD - (Nothing to disclose)
Lyndsey Kilgore, MD – (Nothing to disclose)
Elizabeth Funk, MSW - (Nothing to disclose)
Peter Carpenter, MHA - (Nothing to disclose)